676 related articles for article (PubMed ID: 29105517)
1. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T-cell therapies for multiple myeloma.
Mikkilineni L; Kochenderfer JN
Blood; 2017 Dec; 130(24):2594-2602. PubMed ID: 28928126
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
[TBL] [Abstract][Full Text] [Related]
4. BCMA CAR-T cells in multiple myeloma-ready for take-off?
Scheller L; Tebuka E; Rambau PF; Einsele H; Hudecek M; Prommersberger SR; Danhof S
Leuk Lymphoma; 2024 Feb; 65(2):143-157. PubMed ID: 37997705
[TBL] [Abstract][Full Text] [Related]
5. CAR T and CAR NK cells in multiple myeloma: Expanding the targets.
Shah UA; Mailankody S
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101141. PubMed ID: 32139020
[TBL] [Abstract][Full Text] [Related]
6. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma.
García-Guerrero E; Sierro-Martínez B; Pérez-Simón JA
Front Immunol; 2020; 11():1128. PubMed ID: 32582204
[TBL] [Abstract][Full Text] [Related]
7. Targeting B-cell maturation antigen in multiple myeloma.
Tai YT; Anderson KC
Immunotherapy; 2015; 7(11):1187-99. PubMed ID: 26370838
[TBL] [Abstract][Full Text] [Related]
8. An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis.
Pereira R; Bergantim R
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732213
[TBL] [Abstract][Full Text] [Related]
9. CAR T therapies in multiple myeloma: unleashing the future.
Sheykhhasan M; Ahmadieh-Yazdi A; Vicidomini R; Poondla N; Tanzadehpanah H; Dirbaziyan A; Mahaki H; Manoochehri H; Kalhor N; Dama P
Cancer Gene Ther; 2024 May; 31(5):667-686. PubMed ID: 38438559
[TBL] [Abstract][Full Text] [Related]
10. High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models.
Degagné É; Donohoue PD; Roy S; Scherer J; Fowler TW; Davis RT; Reyes GA; Kwong G; Stanaway M; Larroca Vicena V; Mutha D; Guo R; Edwards L; Schilling B; Shaw M; Smith SC; Kohrs B; Kufeldt HJ; Churchward G; Ruan F; Nyer DB; McSweeney K; Irby MJ; Fuller CK; Banh L; Toh MS; Thompson M; Owen ALG; An Z; Gradia S; Skoble J; Bryan M; Garner E; Kanner SB
Cancer Immunol Res; 2024 Apr; 12(4):462-477. PubMed ID: 38345397
[TBL] [Abstract][Full Text] [Related]
11. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.
Fleischer LC; Spencer HT; Raikar SS
J Hematol Oncol; 2019 Dec; 12(1):141. PubMed ID: 31884955
[TBL] [Abstract][Full Text] [Related]
12. B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases.
Haghikia A; Schett G; Mougiakakos D
Lancet Neurol; 2024 Jun; 23(6):615-624. PubMed ID: 38760099
[TBL] [Abstract][Full Text] [Related]
13. Update on the current and future use of CAR-T to treat multiple myeloma.
Gahvari Z; Brunner M; Schmidt T; Callander NS
Eur J Haematol; 2024 Apr; 112(4):493-503. PubMed ID: 38099401
[TBL] [Abstract][Full Text] [Related]
14. CAR T-cell therapy in multiple myeloma: mission accomplished?
Rasche L; Hudecek M; Einsele H
Blood; 2024 Jan; 143(4):305-310. PubMed ID: 38033289
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.
Hasanali ZS; Razzo B; Susanibar-Adaniya SP; Garfall AL; Stadtmauer EA; Cohen AD
Hematol Oncol Clin North Am; 2024 Apr; 38(2):383-406. PubMed ID: 38158242
[TBL] [Abstract][Full Text] [Related]
16. Future of CAR T cells in multiple myeloma.
Wudhikarn K; Mailankody S; Smith EL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):272-279. PubMed ID: 33275747
[TBL] [Abstract][Full Text] [Related]
17. Designing combination therapies for cancer treatment: application of a mathematical framework combining CAR T-cell immunotherapy and targeted radionuclide therapy.
Adhikarla V; Awuah D; Caserta E; Minnix M; Kuznetsov M; Krishnan A; Wong JYC; Shively JE; Wang X; Pichiorri F; Rockne RC
Front Immunol; 2024; 15():1358478. PubMed ID: 38698840
[TBL] [Abstract][Full Text] [Related]
18. T cell engineering for adoptive T cell therapy: safety and receptor avidity.
D'Ippolito E; Schober K; Nauerth M; Busch DH
Cancer Immunol Immunother; 2019 Oct; 68(10):1701-1712. PubMed ID: 31542797
[TBL] [Abstract][Full Text] [Related]
19. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
[TBL] [Abstract][Full Text] [Related]
20. CAR T cells for solid tumors - developments to watch in 2023.
Trefny MP; Kobold S
Expert Opin Biol Ther; 2024 Apr; 24(4):207-211. PubMed ID: 38526025
[No Abstract] [Full Text] [Related]
[Next] [New Search]
